Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFICIENT pragmatic study
2024-520068-32-00Phase 4Authorised
- Sponsor
- Novo Nordisk
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 52. Planned start Sep 2025; status: authorised.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-520068-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520068-32-00.